<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: The incidence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> has increased despite surveillance of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Limited data indicate that <z:chebi fb="2" ids="35475">nonsteroidal anti-inflammatory drug</z:chebi> (<z:chebi fb="1" ids="35475">NSAID</z:chebi>) and <z:chebi fb="0" ids="35664">statin</z:chebi> use reduce the risk for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated whether <z:chebi fb="1" ids="35475">NSAID</z:chebi> or <z:chebi fb="0" ids="35664">statin</z:chebi> use reduces the risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> from <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We performed a prospective study of 570 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> at 3 academic and 12 regional Dutch hospitals </plain></SENT>
<SENT sid="4" pm="."><plain>Information on medication use was collected in patient interviews at each surveillance visit and cross-checked with pharmacy records </plain></SENT>
<SENT sid="5" pm="."><plain>Patients completed a questionnaire about use of over-the-counter medication </plain></SENT>
<SENT sid="6" pm="."><plain>Incident cases of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were identified during the follow-up period </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: During a median follow-up period of 4.5 years, 38 patients (7%) developed high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>After <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> had been diagnosed, 318 patients (56%) used <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> for a median duration of 2 months, 161 (28%) used aspirin for a median duration of 5 years, 209 (37%) used <z:chebi fb="0" ids="35664">statins</z:chebi> for a median duration of 5 years, and 107 (19%) used <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="1" ids="35475">NSAID</z:chebi> and <z:chebi fb="0" ids="35664">statin</z:chebi> use were each associated with a reduced risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> (hazard ratio [HR], 0.47; P = .030 and HR, 0.46; P = .048, respectively) </plain></SENT>
<SENT sid="10" pm="."><plain>Use of a combination of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> increased the protective effect (HR, 0.22; P = .028) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="1" ids="35475">NSAID</z:chebi> and <z:chebi fb="0" ids="35664">statin</z:chebi> use reduce the risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Use of a combination of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> appears to have an additive protective effect </plain></SENT>
</text></document>